According to American Cancer Society approximately 175 500 people will be diagnosed and 165 000 people died by Lung Cancer or Mesothelioma every year in the US. Over 800,000 people worldwide dies of non-small cell Lung Cancer or Mesothelioma (NSCLC) each year.
More people die of Lung Cancer or Mesothelioma than of colon, breast, and prostate cancers combined. According to analysts, the NSCLC drug market is predicted to exceed $4 billion within a 5-7 year period.
Chemotherapy drugs will experience generic erosion and three major chemotherapy drugs go off patent before 2012, Aventis' Taxotere (docetaxel), Bristol-Myers Squibb's Paraplatin (carboplatin) and Eli Lilly's Gemzar (gemcitabine).
In a recent guideline the expert panel of the ASCO has updated their clinical practice guidelines for the treatment of NSCLC. In the guideline of 2004-2005 Iressa has been recommended as third line treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies.
There are today no less than 234 emerging therapeutics targeting Lung Cancer or Mesothelioma, from early preclinical to Phase III clinical studies.
Lung Cancer or Mesothelioma Drug Pipeline Update lists all 244 drugs for Lung Cancer or Mesothelioma and gives you a progress analysis on each one of them. Read more below how Lung Cancer or Mesothelioma Drug Pipeline Update is organized:
Developmental stage Contains in total 243 Lung Cancer or Mesothelioma drugs in development:
- 28 marketed drugs
- 17 projects in Phase 3
- 122 projects in Phase 2
- 35 projects in Phase 1
- 43 projects in Pre clinical trials
Line of treatment Major lines of treatment for cancer, including:
- Antiangiogenesis
- Apoptosis
- Cell cycle inhibitors
- Cell therapy
- Gene therapy
- Immunomodulator
- Vaccines
Etc.
Mechanism includes more than 110 mechanisms of action:
- Apoptosis agonist
- DNA topoisomerase inhibitor
- Microtubule stimulant
- Beta tubulin antagonist
- Tubulin antagonist & Microtubule inhibitor
- Thymidylate syntheses inhibitor
- DNA antagonist
- ErbB inhibitor
- Angiogenesis inhibitor
- DNA topoisomerase ATP hydrolysing inhibitor
- DNA antagonist
- Endothelial growth factor receptor kinas’ inhibitor
- p21 stimulant
- Microtubule inhibitor
- Dihydrofolate reductase inhibitor
Etc.
Target Drug targets for more than 100 drugs is available.
Examples:
-ATP-binding cassette, subfamily B (MDR/TAP), member 1
- Caspase 3
- Colony stimulating factor 2 and 3
- Thymidylate synthetase sulphate
- topoisomerase (DNA) 1
- tubulin, beta polypeptide hydrochlorides
- Cyclin G1
- Cyclin-dependent kinase inhibitor 1A
- kinase insert domain receptor (a type III receptor tyrosine kinase)
- mucin 1, Tran membrane
- DNA (cytosine-5-)-methyl transferase 1
- Epidermal growth factor receptor
- Eukaryotic translation elongation factor 1 alpha 1
Compound Lists compound name or type of compound:
- Antibodies
- Chemical names
- Enzymes
- Nucleotides
- Peptides
- Proteins
- Ribozymes
Etc.
Description Progress analysis and review of newly innovated drugs:
How May Drug Pipeline Update Be of Use?
Show investors/board/management that you are right on top of drug development progress in your therapeutic area. Find competitors, collaborations partners, M&A candidates etc. Jump-start competitive drug intelligence operations and excellent starting point for world wide benchmarking. Compare portfolio and therapy focus with your peers.
Speed up pro-active in-/outlicensing strategy work. Fast and easy way of tracking drugs using search engines; just one click and you may search World Wide Web and PubMed for any drug with all its synonyms.